Derik De Bruin
Stock Analyst at B of A Securities
(4.49)
# 316
Out of 4,996 analysts
220
Total ratings
64.19%
Success rate
14.5%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MTD Mettler-Toledo International | Maintains: Neutral | $1,260 → $1,390 | $1,204.43 | +15.41% | 11 | Sep 22, 2025 | |
| DHR Danaher | Maintains: Buy | $230 → $220 | $184.84 | +19.02% | 5 | Sep 22, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underperform | $19 → $27 | $38.81 | -30.43% | 5 | Aug 29, 2025 | |
| RVTY Revvity | Maintains: Buy | $116 → $110 | $84.06 | +30.86% | 3 | Jun 26, 2025 | |
| BRKR Bruker | Maintains: Buy | $61 → $50 | $31.04 | +61.08% | 13 | Jun 26, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $13 | $11.72 | +10.92% | 9 | Jun 26, 2025 | |
| QGEN Qiagen | Maintains: Buy | $50 → $53 | $43.90 | +20.73% | 6 | Jun 26, 2025 | |
| WAT Waters | Maintains: Neutral | $370 → $375 | $291.71 | +28.55% | 14 | Jun 26, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $156 → $128 | $123.39 | +3.74% | 33 | Apr 14, 2025 | |
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $7.70 | +42.86% | 13 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $65 | $53.57 | +21.34% | 7 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $16 | $7.93 | +101.77% | 5 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $675 → $660 | $464.24 | +42.17% | 18 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $255 → $235 | $179.56 | +30.88% | 3 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $220 → $210 | $148.56 | +41.36% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $355 | $261.52 | +35.74% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $25.66 | +1.33% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $280.61 | -3.42% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $188.99 | -3.70% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $8.68 | +141.94% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $19.30 | +65.80% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $91.69 | +9.06% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $67.21 | +27.96% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $3.48 | +273.56% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $2.27 | +186.34% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $163.79 | +58.74% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $11.50 | +943.48% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $143.50 | -16.38% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $3.11 | +189.39% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $632.22 | -62.83% | 3 | Nov 2, 2018 |
Mettler-Toledo International
Sep 22, 2025
Maintains: Neutral
Price Target: $1,260 → $1,390
Current: $1,204.43
Upside: +15.41%
Danaher
Sep 22, 2025
Maintains: Buy
Price Target: $230 → $220
Current: $184.84
Upside: +19.02%
Phibro Animal Health
Aug 29, 2025
Maintains: Underperform
Price Target: $19 → $27
Current: $38.81
Upside: -30.43%
Revvity
Jun 26, 2025
Maintains: Buy
Price Target: $116 → $110
Current: $84.06
Upside: +30.86%
Bruker
Jun 26, 2025
Maintains: Buy
Price Target: $61 → $50
Current: $31.04
Upside: +61.08%
10x Genomics
Jun 26, 2025
Maintains: Neutral
Price Target: $12 → $13
Current: $11.72
Upside: +10.92%
Qiagen
Jun 26, 2025
Maintains: Buy
Price Target: $50 → $53
Current: $43.90
Upside: +20.73%
Waters
Jun 26, 2025
Maintains: Neutral
Price Target: $370 → $375
Current: $291.71
Upside: +28.55%
Agilent Technologies
Apr 14, 2025
Maintains: Neutral
Price Target: $156 → $128
Current: $123.39
Upside: +3.74%
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $7.70
Upside: +42.86%
Feb 20, 2025
Maintains: Buy
Price Target: $72 → $65
Current: $53.57
Upside: +21.34%
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $7.93
Upside: +101.77%
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $464.24
Upside: +42.17%
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $179.56
Upside: +30.88%
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $148.56
Upside: +41.36%
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $261.52
Upside: +35.74%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $25.66
Upside: +1.33%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $280.61
Upside: -3.42%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $188.99
Upside: -3.70%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $8.68
Upside: +141.94%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $19.30
Upside: +65.80%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $91.69
Upside: +9.06%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $67.21
Upside: +27.96%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $3.48
Upside: +273.56%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $2.27
Upside: +186.34%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $163.79
Upside: +58.74%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $11.50
Upside: +943.48%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $143.50
Upside: -16.38%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $3.11
Upside: +189.39%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $632.22
Upside: -62.83%